Literature DB >> 11596831

Pharmacoeconomic fellowships: the need for outcome measures.

V Maio1, T K Girts, J H Lofland, D B Nash.   

Abstract

Pharmacoeconomic fellowship programmes have been in existence for more than 10 years, but their effectiveness has not been evaluated. The aim of this project was to construct a framework to examine the potential outcome measures for pharmacoeconomic fellowships so that the effectiveness of these programmes may be determined. Using the Donabedian model, the structures, processes, and outcomes of pharmacoeconomic fellowship programmes were investigated. The structures of these programmes include the facilities, qualifications of the teaching staff and organisation, and operations of the institution. Most pharmacoeconomic fellowships are based in academic institutions and the pharmaceutical industry. Credentials of the preceptors and teaching staff consist of an advanced degree and relevant expertise in pharmacoeconomics and outcomes research. The processes of pharmacoeconomic fellowships include the duration of the programme as well as the research skills and the educational components taught. However, current guidelines do not define outcome measures for these pharmacoeconomic fellowships. Potential outcomes may include whether or not a degree was obtained, the management and research skills acquired, as well as the type of experiential training received. Further research is required to develop these outcome measures, so the effectiveness of pharmacoeconomic fellowship programmes may be assessed.

Mesh:

Year:  2001        PMID: 11596831     DOI: 10.2165/00019053-200119080-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  14 in total

1.  Pharmacoeconomic analyses: making them transparent, making them credible.

Authors:  D Rennie; H S Luft
Journal:  JAMA       Date:  2000-04-26       Impact factor: 56.272

2.  Conflict of interest and cost-effectiveness analysis.

Authors:  S Krimsky
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

3.  Using economic evaluations to make formulary coverage decisions. So much for guidelines.

Authors:  A H Anis; Y Gagnon
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

4.  Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

Authors:  I S Udvarhelyi; G A Colditz; A Rai; A M Epstein
Journal:  Ann Intern Med       Date:  1992-02-01       Impact factor: 25.391

Review 5.  Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature.

Authors:  J T Lee; L A Sanchez
Journal:  Am J Hosp Pharm       Date:  1991-12

6.  Emerging standardization in pharmacoeconomics.

Authors:  C D Mullins; S Ogilvie
Journal:  Clin Ther       Date:  1998 Nov-Dec       Impact factor: 3.393

7.  Definitions of pharmacy residencies and fellowships.

Authors: 
Journal:  Am J Hosp Pharm       Date:  1987-05

8.  The pharmacoeconomist--an emerging specialist in health care institutions.

Authors:  A D St Jean; N T Lándis
Journal:  Am J Hosp Pharm       Date:  1993-06

9.  Pharmacoeconomics: is a drug worth its cost?

Authors:  C Marwick
Journal:  JAMA       Date:  1994-11-09       Impact factor: 56.272

10.  The role of colleges of pharmacy in meeting the pharmacoeconomic needs of the pharmaceutical industry: a conference report.

Authors:  J R Draugalis; S J Coons
Journal:  Clin Ther       Date:  1994 May-Jun       Impact factor: 3.393

View more
  2 in total

1.  Outcome measures for pharmacoeconomics education.

Authors:  Vittorio Maio; Jennifer H Lofland
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  Education in pharmacoeconomics: an international multidisciplinary view.

Authors:  Karen L Rascati; Michael F Drummond; Lieven Annemans; Peter G Davey
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.